Payment overview · 2025
General Payments
$278.83
14 reported records · 9 companies
Healthcare provider profile · identity verified
Christopher Todd Nelson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GRAY COURT, SC · NPI 1558305029
Verified facts
What the public records show
CMS Open Payments records show Christopher Todd Nelson, M.D. received $278.83 in general payments during 2025 across 14 reported records.
PFIZER INC. accounted for 22.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Linzess, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Shingrix by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 274 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $61.47 | 22.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $47.01 | 16.9% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $36.14 | 13.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26.66 | 9.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $25.48 | 9.1% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $22.58 | 8.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.25 | 8.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.59 | 7.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.65 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $278.83 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $61.47 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $61.47 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $36.14 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $30.47 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $26.66 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $25.48 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $22.58 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $22.25 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 274 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 140 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 26 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
140 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
26 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
274 | 37 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 937 | 208 |
| Amlodipine Besylate | Amlodipine Besylate | 753 | 163 |
| Gabapentin | Gabapentin | 643 | 125 |
| Losartan Potassium | Losartan Potassium | 592 | 134 |
| Potassium Chloride | Potassium Chloride | 550 | 100 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 507 | 146 |
| Levothyroxine Sodium | Levothyroxine Sodium | 499 | 88 |
| Omeprazole | Omeprazole | 495 | 104 |
| Famotidine | Famotidine | 468 | 106 |
| Furosemide | Furosemide | 464 | 89 |
| Fluticasone Propionate | Fluticasone Propionate | 441 | 166 |
| Metoprolol Succinate | Metoprolol Succinate | 419 | 96 |
| Tamsulosin Hcl | Tamsulosin Hcl | 396 | 75 |
| Pravastatin Sodium | Pravastatin Sodium | 379 | 74 |
| Lisinopril | Lisinopril | 377 | 86 |
| Montelukast Sodium | Montelukast Sodium | 367 | 72 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 329 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 322 | 71 |
| Metformin Hcl Er | Metformin Hcl | 316 | 72 |
| Trazodone Hcl | Trazodone Hcl | 288 | 69 |
| Eliquis | Apixaban | 274 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 264 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 255 | 59 |
| Carvedilol | Carvedilol | 234 | 43 |
| Mirtazapine | Mirtazapine | 231 | 36 |
| Metformin Hcl | Metformin Hcl | 225 | 56 |
| Buspirone Hcl | Buspirone Hcl | 204 | 41 |
| Diclofenac Sodium | Diclofenac Sodium | 192 | 60 |
| Memantine Hcl | Memantine Hcl | 191 | 28 |
| Sertraline Hcl | Sertraline Hcl | 191 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 190 | 57 |
| Allopurinol | Allopurinol | 182 | 40 |
| Donepezil Hcl | Donepezil Hcl | 172 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 172 | 30 |
| Simvastatin | Simvastatin | 156 | 32 |
| Irbesartan | Irbesartan | 151 | 30 |
| Spironolactone | Spironolactone | 150 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 145 | 34 |
| Jardiance | Empagliflozin | 140 | 22 |
| Tramadol Hcl | Tramadol Hcl | 132 | 36 |
| Finasteride | Finasteride | 127 | 31 |
| Alendronate Sodium | Alendronate Sodium | 122 | 27 |
| Clonazepam | Clonazepam | 122 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 121 | 60 |
| Pioglitazone Hcl | Pioglitazone Hcl | 121 | 23 |
| Bupropion Hcl Sr | Bupropion Hcl | 118 | 21 |
| Lorazepam | Lorazepam | 118 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 114 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 110 | 30 |
| Xarelto | Rivaroxaban | 110 | 14 |
| Alprazolam | Alprazolam | 107 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 104 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 102 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 99 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 94 | 29 |
| Paroxetine Hcl | Paroxetine Hcl | 92 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 92 | 52 |
| Atenolol | Atenolol | 87 | 18 |
| Warfarin Sodium | Warfarin Sodium | 87 | 21 |
| Prednisone | Prednisone | 85 | 47 |
| Glimepiride | Glimepiride | 79 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 77 | 15 |
| Levetiracetam | Levetiracetam | 76 | 11 |
| Diazepam | Diazepam | 75 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 74 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 15 |
| Meloxicam | Meloxicam | 64 | 19 |
| Farxiga | Dapagliflozin Propanediol | 62 | suppressed |
| Nitroglycerin | Nitroglycerin | 62 | 43 |
| Ketoconazole | Ketoconazole | 60 | 15 |
| Meclizine Hcl | Meclizine Hcl | 59 | 21 |
| Torsemide | Torsemide | 58 | 17 |
| Divalproex Sodium Er | Divalproex Sodium | 55 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 54 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 54 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 53 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 51 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 14 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 51 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | suppressed |
| Valsartan | Valsartan | 46 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 45 | 11 |
| Ezetimibe | Ezetimibe | 45 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 11 |
| Digoxin | Digoxin | 43 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 41 | suppressed |
| Ozempic | Semaglutide | 40 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 39 | suppressed |
| Azithromycin | Azithromycin | 38 | 33 |
| Cilostazol | Cilostazol | 38 | 11 |
| Linzess | Linaclotide | 38 | suppressed |
| Pregabalin | Pregabalin | 38 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 34 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 34 | 28 |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 31 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 31 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Cephalexin | Cephalexin | 27 | 22 |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 26 | 24 |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Klor-Con M10 | Potassium Chloride | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 16 |
| Novolin N Flexpen | Insulin Nph Human Isophane | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 16 |
| Risperidone | Risperidone | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Cefdinir | Cefdinir | 20 | 18 |
| Ondansetron Odt | Ondansetron | 20 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 18 |
| Celecoxib | Celecoxib | 19 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | 11 |
| Probenecid-Colchicine | Probenecid/Colchicine | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 18 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 18 | 18 |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Clotrimazole | Clotrimazole | 16 | 11 |
| Colchicine | Colchicine | 16 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 16 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Probenecid | Probenecid | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 11 | 11 |
| Olanzapine | Olanzapine | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $278.83 · 14 records | PFIZER INC. | AIRSUPRA, AREXVY, Cologuard Collection Kit, Doc Band, ELIQUIS, GVOKE HYPOPEN, INSPIRE, JARDIANCE, LINZESS, NURTEC ODT, SHINGRIX, The Cologuard Plus Collection Kit | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error